Last reviewed · How we verify

Pectdrill (carbocisteine)

unknown active ✓ Verified May 2026

Pectdrill (generic name: carbocisteine) is a carbocisteine drug. It is currently in unknown development.

Carbocisteine works by breaking down and clearing mucus from the lungs, making it easier to breathe.

Carbocisteine is a small molecule that acts as a mucolytic, reducing the viscosity of sputum. It is used to relieve symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by facilitating easier sputum expulsion.

At a glance

Generic namecarbocisteine
Drug classcarbocisteine
Therapeutic areaRespiratory
Phaseunknown

Mechanism of action

Imagine your lungs are clogged with sticky mucus. Carbocisteine helps to break down this mucus, making it easier to cough up and breathe more easily. This can be especially helpful for people with conditions like chronic bronchitis or cystic fibrosis.

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pectdrill

What is Pectdrill?

Pectdrill (carbocisteine) is a carbocisteine drug.

How does Pectdrill work?

Carbocisteine works by breaking down and clearing mucus from the lungs, making it easier to breathe.

What is the generic name of Pectdrill?

carbocisteine is the generic (nonproprietary) name of Pectdrill.

What drug class is Pectdrill in?

Pectdrill belongs to the carbocisteine class. See all carbocisteine drugs at /class/carbocisteine.

What development phase is Pectdrill in?

Pectdrill is in unknown.

What are the side effects of Pectdrill?

Common side effects of Pectdrill include Interstitial lung disease, Hepatic function abnormal, Pulmonary pain, Pneumonia, Upper respiratory tract inflammation, Lower respiratory tract infection.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing